This is a routine execution of a previously announced restructuring plan. No immediate trading signal. Monitor the next 10-Q for updates on the restructuring's financial impact and any further headcount reductions.
Price Chart
Executive Summary
Theravance Biopharma disclosed the planned departure of SVP Development and Head of Ireland Office, Dr. ine Miller, effective November 15, 2026, under a compromise agreement tied to the restructuring announced in March 2026. The filing includes a grant of 18,750 RSUs and a $250,000 pension contribution. This is a routine, previously anticipated executive exit with no unexpected C-suite changes.
Key Facts
- Dr. ine Miller, SVP Development and Head of Ireland Office, will terminate employment on November 15, 2026.
- Departure is part of the restructuring announced by the company in March 2026.
- Dr. Miller received a grant of 18,750 restricted share units on June 19, 2026.
- The company will make a special pension contribution of $250,000 within 30 days of the termination date.
- CEO Rick E. Winningham remains in place; no other executive changes disclosed.
Financial Impact
Total disclosed cash cost of $250,000 pension contribution plus 18,750 RSUs; immaterial relative to $854M market cap.
Risk Factors
- Restructuring may signal ongoing operational challenges or cost pressures.
- Further executive departures could indicate deeper organizational issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076857 |
| Document: 0001104659-26-076857-index-headers.html | 0001104659-26-076857 |
| Document: 0001104659-26-076857-index.html | 0001104659-26-076857 |
| Document: 0001104659-26-076857.txt | 0001104659-26-076857 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access